Akouos (AKUS) Stock Analysis

What Akouos does

Akouos, Inc. is a company dedicated to precise genetic medicine, developing gene therapies with the aim of restoring, enhancing, and safeguarding individuals' natural auditory function. Central to its strategy is an advanced genetic medicine platform, which incorporates a proprietary library of adeno-associated viral vectors and an innovative delivery method. The firm's leading experimental therapy is AK-OTOF, a gene therapy designed to treat hearing impairment caused by mutations in the OTOF gene. Additionally, Akouos is advancing AK-CLRN1 for the auditory symptoms linked to Usher syndrome type 3A (USH3A), and AK-antiVEGF for addressing vestibular schwannoma. The company's comprehensive genetic platform further addresses hearing loss related to genes essential for supporting cell function. Founded in 2016, Akouos, Inc. is headquartered in Boston, Massachusetts.

Key metrics

ETFs linked to AKUS

Broad-market and Healthcare sector ETFs an investor holding Akouos is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AKUS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Akouos?

Akouos trades under the ticker AKUS on NASDAQ.

Which exchange is AKUS listed on?

AKUS is listed on NASDAQ.

What sector does Akouos operate in?

Akouos is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AKUS in a portfolio?

PortView shows AKUS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.